Keyphrases
Overall Survival
68%
Cancer-associated Venous Thromboembolism
68%
In Cancer
45%
Therapeutic Plasma Exchange
45%
Confidence Interval
45%
Cancer-associated Thrombosis
45%
Low Molecular Weight Heparin
45%
Warfarin
45%
Renal Response
45%
Myeloma Cast Nephropathy
45%
Multiple Myeloma
45%
Hazard Ratio
45%
Response Rate
30%
Very Good Partial Response
22%
Free Light Chains
22%
Odds Ratio
22%
Venous Thromboembolism
22%
Median Overall Survival
15%
Omacetaxine
15%
Daratumumab
15%
Cancer Stage
15%
Dialysis
15%
Hematological Response
15%
Cancer Treatment
15%
Cancer Diagnosis
15%
Survival Benefit
15%
Multivariable
15%
Cox Proportional Hazards Regression
7%
Linked Database
7%
Propensity Score Matching
7%
Ovarian Cancer
7%
Recurrent Venous Thromboembolism
7%
Patient Survival
7%
Multi-institutional Study
7%
Comorbidity Burden
7%
Brain Cancer
7%
Medicare Beneficiaries
7%
Clinical Practice Guidelines
7%
Medicare
7%
Surveillance Epidemiology
7%
Age of Diagnosis
7%
Systemic Therapy
7%
Exact Matching
7%
Poor Survival
7%
Newly Diagnosed
7%
Cancer Hazard
7%
Lung
7%
Baseline Creatinine
7%
Plasma Cells
7%
Population-based Study
7%
Medicine and Dentistry
Overall Survival
100%
Malignant Neoplasm
90%
Venous Thromboembolism
90%
Warfarin
90%
Low Molecular Weight Heparin
50%
Hazard Ratio
48%
Cohort Analysis
45%
Plasma Exchange
45%
Multiple Myeloma
45%
Thrombosis
45%
Myeloma Cast Nephropathy
45%
Direct Oral Anticoagulant
45%
Odds Ratio
27%
Light Chain
27%
Cancer Staging
26%
Ponatinib
22%
Cancer Diagnosis
22%
Cancer Treatment
22%
Daratumumab
18%
Medicare
17%
Ovarian Cancer
11%
Surveillance, Epidemiology, and End Results
11%
Propensity Score Matching
11%
Brain Cancer
11%
Creatinine
9%
Plasma Cell
9%
Cancer Localization
9%
Systemic Therapy
9%
Disease
9%
Stomach Cancer
6%
Proportional Hazards Model
6%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
90%
Venous Thromboembolism
90%
Warfarin
90%
Overall Survival
67%
Low Molecular Weight Heparin
50%
Myeloid Leukemia
45%
Lorlatinib
45%
Bortezomib
45%
Multiple Myeloma
45%
Thrombosis
45%
Cohort Study
45%
Direct Oral Anticoagulant
45%
Comorbidity
29%
Cancer Staging
26%
Ponatinib
22%
Imatinib
22%
Side Effect
22%
Nilotinib
22%
Bosutinib
22%
Dasatinib
22%
Brain Cancer
11%
Ovary Cancer
11%
Peripheral Neuropathy
7%
Stomach Cancer
6%